Floatz logo

Wellbutrin

Weight Loss

Mayo ClinicPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

6 Active assets in the Weight Loss cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 2B
Xeomin®
Tan Tock Seng Hospital
Phase 2/3CCC
Cediranib
City of Hope Medical Center
Phase 1CC
Bacitracin
Assaf Harofeh MC
N/AD
NEOMYCIN
Assaf Harofeh MC
N/AD

View all 9 →

Same molecule, other indications

Wellbutrin is also rated in:

Smoking CessationDormant
A
Indicative ·
82 / 100
View asset →
DysthymiaDormant
BBB
Indicative ·
73 / 100
View asset →
depressive disorderDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →